Free tool
FAERS Monitor: Lotemax Sm
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208219 or its brand name (Lotemax Sm, Loteprednol Etabonate). Reports on generic versions are filed under their own applications.
Reports
944
Serious
290
31% of reports
Hospitalization
82
Death reported
15
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain163
- eye irritation116
- vision blurred74
- product use in unapproved indication72
- off label use67
- drug ineffective60
- headache56
- ocular hyperaemia53
- photophobia47
- product dose omission issue45
- fatigue40
- inappropriate schedule of product administration40
- eye swelling39
- pruritus38
- lacrimation increased35
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 3 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 8 |
| 2016 | 5 |
| 2017 | 6 |
| 2018 | 11 |
| 2019 | 50 |
| 2020 | 73 |
| 2021 | 88 |
| 2022 | 132 |
| 2023 | 133 |
| 2024 | 157 |
| 2025 | 135 |
| 2026 | 120 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,215 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye painSignal | 163 | 64.6 | 56.1 | 10,133 |
| photophobiaSignal | 47 | 55.8 | 42.2 | 2,471 |
| eye irritationSignal | 116 | 45.0 | 37.9 | 4,949 |
| lacrimation increasedSignal | 35 | 25.8 | 18.7 | 811 |
| ocular hyperaemiaSignal | 53 | 24.9 | 19.2 | 1,194 |
| eye swellingSignal | 39 | 23.4 | 17.2 | 814 |
| vision blurredSignal | 74 | 12.0 | 9.7 | 741 |
| product use in unapproved indicationSignal | 72 | 6.5 | 5.2 | 332 |
| inappropriate schedule of product administrationSignal | 40 | 4.9 | 3.7 | 123 |
| product dose omission issueSignal | 45 | 3.4 | 2.6 | 75 |
| pruritusSignal | 38 | 2.2 | 1.6 | 24 |
| headache | 56 | 2.0 | 1.5 | 27 |
| off label use | 67 | 1.7 | 1.4 | 20 |
| fatigue | 40 | 1.1 | 0.8 | 1 |
| drug ineffective | 60 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.